The Winter 2020 edition of the newsletter on SWOG's Lung-MAP precision medicine trial is out. Lung-MAP is NCI's first precision trial, and tests new treatments for non-small cell cancer in partnership with the National Cancer Institute, Foundation for the National Institutes of Health, and Friends of Cancer Research.

The newsletter gives a grateful accounting of progress made during this remarkable year, with over 900 study registrations. It also also includes links to the latest Lung-MAP manuscript, published in The Lancet Oncology, and a list of new study leaders. Read the newsletter here.

Other Recent Stories

Results of S1417CD
Jan 4, 2022
Major financial hardship common after cancer diagnosis, despite insurance